Synergistic Benefit of Statin and Metformin in Gastrointestinal Malignancies
| Autor: | Jennifer L. Donato, Zachary A.P. Wintrob, Dmitriy A. Sulik, George K. Nimako, Alice C. Ceacareanu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Male medicine.medical_specialty Statin medicine.drug_class Pharmacology Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus medicine Diabetes Mellitus Humans Hypoglycemic Agents Pharmacology (medical) In patient Gastrointestinal cancer Aged Gastrointestinal Neoplasms Retrospective Studies Aged 80 and over business.industry Cancer Drug Synergism Statin treatment Middle Aged medicine.disease Metformin Survival Rate 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Drug Therapy Combination Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of pharmacy practice. 30(2) |
| ISSN: | 1531-1937 |
| Popis: | Objectives: To evaluate whether statin use influences gastrointestinal cancer prognosis in patients with diabetes mellitus (DM). Methods: We reviewed all DM patients diagnosed at Roswell Park Cancer Institute with emergent gastrointestinal malignancy (January 2003 to December 2010) (N = 222). Baseline demographic, clinical history, and cancer outcomes were documented. Overall survival (OS) and disease-free survival (DFS) comparisons across various treatment groups were assessed by Kaplan-Meier and Cox proportional hazards. Results: Use of statin, alone or in combination, was associated with improved OS and DFS (hazard ratio [HR] = 0.65, P = .06; HR = 0.60, P < .02). We report similar OS and DFS advantage among users of mono- or combined metformin therapy (HR = 0.55, P < .01; HR = 0.63, P < .02). Concomitant use of metformin and statin provided a synergistic OS and DFS benefit (HR = 0.42, P < .01; HR = 0.44, P < .01). Despite significant tobacco and alcohol use history, patients with upper gastrointestinal cancers derived enhanced cancer outcomes from this combination (HR = 0.34, P < .01; HR = 0.43, P < .02), while receiving a statin without metformin or metformin without a statin did not provide significant cancer-related benefits. Conclusion: Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|